CA2123315C - Therapeutic agents which are antagonists or partial agonists of human interleukin 4 - Google Patents

Therapeutic agents which are antagonists or partial agonists of human interleukin 4 Download PDF

Info

Publication number
CA2123315C
CA2123315C CA002123315A CA2123315A CA2123315C CA 2123315 C CA2123315 C CA 2123315C CA 002123315 A CA002123315 A CA 002123315A CA 2123315 A CA2123315 A CA 2123315A CA 2123315 C CA2123315 C CA 2123315C
Authority
CA
Canada
Prior art keywords
hil
protein
amino acid
mutant
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002123315A
Other languages
English (en)
French (fr)
Other versions
CA2123315A1 (en
Inventor
Walter Sebald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6444719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2123315(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG filed Critical Bayer AG
Publication of CA2123315A1 publication Critical patent/CA2123315A1/en
Application granted granted Critical
Publication of CA2123315C publication Critical patent/CA2123315C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002123315A 1991-11-13 1992-11-13 Therapeutic agents which are antagonists or partial agonists of human interleukin 4 Expired - Lifetime CA2123315C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4137333A DE4137333A1 (de) 1991-11-13 1991-11-13 Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
DEP4137333.2 1991-11-13
PCT/EP1992/002614 WO1993010235A1 (de) 1991-11-13 1992-11-13 Menschliche il-4 mutantenproteine

Publications (2)

Publication Number Publication Date
CA2123315A1 CA2123315A1 (en) 1993-05-27
CA2123315C true CA2123315C (en) 2003-06-17

Family

ID=6444719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002123315A Expired - Lifetime CA2123315C (en) 1991-11-13 1992-11-13 Therapeutic agents which are antagonists or partial agonists of human interleukin 4

Country Status (16)

Country Link
US (1) US5723118A (hu)
EP (1) EP0613499B2 (hu)
JP (2) JP3470970B2 (hu)
KR (1) KR100276410B1 (hu)
AT (1) ATE163196T1 (hu)
AU (1) AU671960B2 (hu)
CA (1) CA2123315C (hu)
CZ (1) CZ283467B6 (hu)
DE (2) DE4137333A1 (hu)
DK (1) DK0613499T4 (hu)
ES (1) ES2112340T5 (hu)
GR (1) GR3026600T3 (hu)
HU (1) HU217326B (hu)
NO (1) NO312707B1 (hu)
SK (1) SK280114B6 (hu)
WO (1) WO1993010235A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
CA2256459A1 (en) * 1996-06-14 1997-12-18 Bayer Corporation T-cell selective interleukin-4 agonists
MY124565A (en) * 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
DE10022258A1 (de) 2000-05-08 2001-11-15 Bayer Ag Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
EP1314739A1 (en) * 2001-11-22 2003-05-28 Bayer Ag Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
BRPI0713484A2 (pt) * 2006-06-21 2012-11-06 Apogenix Gmbh expressão diferencial de citocina em cáncer humano
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
EP2596802A1 (en) 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
EP2674168A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Modulation of effector T cell responses by local depletion of complement component C3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
ES2058490T3 (es) * 1988-02-02 1994-11-01 Schering Biotech Corp Metodo de reducir respuestas de inmunoglobulina e.
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels

Also Published As

Publication number Publication date
HUT66826A (en) 1995-01-30
DK0613499T4 (da) 2005-04-18
AU2928292A (en) 1993-06-15
GR3026600T3 (en) 1998-07-31
CZ283467B6 (cs) 1998-04-15
CZ118594A3 (en) 1994-12-15
CA2123315A1 (en) 1993-05-27
NO941681L (no) 1994-05-06
NO941681D0 (no) 1994-05-06
HU217326B (hu) 1999-12-28
JPH07501522A (ja) 1995-02-16
EP0613499B1 (de) 1998-02-11
SK280114B6 (sk) 1999-08-06
ES2112340T5 (es) 2005-10-16
JP3470970B2 (ja) 2003-11-25
DE59209196D1 (de) 1998-03-19
HU9401369D0 (en) 1994-08-29
SK55494A3 (en) 1994-12-07
ATE163196T1 (de) 1998-02-15
JP2003174894A (ja) 2003-06-24
US5723118A (en) 1998-03-03
EP0613499A1 (de) 1994-09-07
WO1993010235A1 (de) 1993-05-27
DE4137333A1 (de) 1993-05-19
KR100276410B1 (ko) 2000-12-15
NO312707B1 (no) 2002-06-24
DK0613499T3 (da) 1998-09-23
EP0613499B2 (de) 2005-03-30
ES2112340T3 (es) 1998-04-01
AU671960B2 (en) 1996-09-19

Similar Documents

Publication Publication Date Title
CA2123315C (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
Gubler et al. Recombinant human interleukin 1 alpha: purification and biological characterization.
Le et al. Biology of disease
Zhang et al. Structure and function of interleukin-17 family cytokines
Postlethwaite et al. Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122.
JP4423313B2 (ja) ナチュラルキラー刺激因子
Ju et al. Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis.
US6313272B1 (en) DNA encoding high affinity interleukin-4 muteins
IL182509A (en) A method for determining an affinity between a mutine and a receptor
DeChiara et al. Structure-function analysis of murine interleukin 1: biologically active polypeptides are at least 127 amino acids long and are derived from the carboxyl terminus of a 270-amino acid precursor.
Vandergrifft et al. Molecular cloning and sequencing of equine interleukin 4
Fiorillo et al. Analysis of human/mouse interleukin‐6 hybrid proteins: both amino and carboxy termini of human interleukin‐6 are required for in vitro receptor binding
Seow et al. Cloning and sequencing an ovine interleukin-4-encoding cDNA
CA2251355C (en) Il-6 mutein
JP3652365B6 (ja) ナチュラルキラー刺激因子
AU742384B2 (en) High affinity interleukin-4 muteins
Delespesse et al. IgE-binding factors: Their possible role in the regulation of IgE synthesis
Brakenhoff et al. Identification of residues in the putative 5th helical region of human interleukin‐6, important for activation of the IL‐6 signal transducer, gp130
IL In Activated Mast Cells, IL-1 Up-Regulates
AU2003271323A1 (en) Keratinocyte derived interferon

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry